Botulism
Clinical Snapshot
Botulism is a rare but severe, toxin-mediated neuroparalytic illness caused by botulinum neurotoxin (BoNT), produced almost always by Clostridium botulinum — a gram-positive, anaerobic, spore-forming bacterium — and only rarely by toxin-producing strains of Clostridium baratii or Clostridium butyricum. Botulinum neurotoxins are the most potent biological toxins known.[1]
The toxin binds irreversibly to presynaptic cholinergic nerve terminals — at the neuromuscular junction and at autonomic synapses — where it cleaves the SNARE proteins required for acetylcholine-containing vesicles to fuse with the nerve terminal membrane. The result is a block of acetylcholine release that only resolves as new nerve terminals regenerate, producing a symmetric, descending flaccid paralysis that begins with the cranial nerves and autonomic findings, and characteristically spares sensation entirely.[1][2] Regardless of how the toxin was acquired, the clinical picture it produces is essentially the same.[2]
There are five recognized routes of exposure: foodborne (ingestion of preformed toxin), wound (spores germinate and produce toxin locally in an anaerobic wound), infant (ingested spores germinate and produce toxin in an immature infant gut), adult intestinal colonization (the same intestinal mechanism as infant botulism, occurring rarely in adults with disrupted gut flora or anatomy), and iatrogenic (unintended systemic spread of therapeutically or cosmetically injected botulinum toxin).[2]
Every suspected case of botulism is a medical emergency. Antitoxin cannot reverse paralysis that has already occurred — it can only halt further progression — so treatment is started on clinical suspicion alone, in parallel with immediate public health notification, never after waiting for laboratory confirmation.[2][1] The pharmacist's role in this condition is recognition and immediate escalation to emergency care, not outpatient assessment or watchful waiting.
Recognize the Condition
The classic pattern
Early symptoms reflect bilateral cranial nerve involvement: blurred or double vision (diplopia), drooping eyelids (ptosis), slurred speech (dysarthria), a hoarse or weak voice (dysphonia), and difficulty swallowing (dysphagia) — sometimes summarized as the "4 Ds": diplopia, dysarthria, dysphonia, and dysphagia.[3] Dry mouth is frequently an early complaint, reflecting the toxin's effect on autonomic cholinergic synapses as well as the neuromuscular junction.[2]
From the cranial nerves, weakness characteristically descends — to the neck and upper extremities, then the trunk and lower extremities, and in severe cases to the muscles of respiration, causing respiratory failure. Autonomic findings often accompany the motor findings: dilated or sluggishly reactive pupils, ileus, constipation, and urinary retention.[1][2]
Two negative findings that matter as much as the positive ones
Two features are genuinely central to recognizing botulism, precisely because their presence should make the diagnosis less likely: patients are classically afebrile (fever occurs only if a complicating infection is also present), and fully alert and oriented with no sensory findings whatsoever — paradoxically mentally intact despite advancing paralysis.[2][1] This combination — afebrile, mentally intact, symmetric descending paralysis without sensory loss — is the single most useful bedside clue distinguishing botulism from its principal mimics (see Assessment & Diagnosis).[1]
Presentation by subtype
How each route of exposure typically presents
Foodborne
Incubation is typically 12-72 hours (range 2 hours to 8 days) after ingesting preformed toxin; the shorter the incubation, the more severe the illness and the higher the case-fatality rate. Gastrointestinal symptoms — nausea, vomiting, constipation or, less often, diarrhea, and abdominal swelling — often accompany or precede the neurologic findings.[2]
Wound
Incubation is longer, about 7 days (range 4-14 days), and there is no GI prodrome. The neurologic picture is otherwise the same as foodborne disease. The wound itself may look entirely unremarkable — do not let a benign-appearing injection site lower suspicion in an at-risk patient (see Risk Factors and Special Populations).[2]
Infant
The most commonly reported form of botulism in North America. It typically begins with constipation, sometimes days before any other sign, followed by poor feeding, a weak or altered cry, loss of head control, a diminished gag reflex, ptosis and other cranial nerve palsies, and progressive hypotonia — the classic "floppy baby." Severity ranges from mild illness to sudden, unexplained respiratory arrest; progression tends to be more severe in infants younger than 2 months. Nearly all infant cases are caused by toxin type A or B.[2][1]
Iatrogenic
Follows unintended systemic spread of a therapeutically or cosmetically injected botulinum toxin product, with an incubation of days to weeks. It can occur even at doses used for routine cosmetic indications, though most reported outbreaks involve unregulated or counterfeit product, or a dose and injection site well outside approved use.[4][5]
Adult intestinal colonization
A very rare form affecting older children and adults whose gut flora or anatomy has been disrupted (recent antimicrobial use, inflammatory bowel disease, prior GI surgery), allowing ingested spores to germinate and produce toxin intraluminally, as in infant botulism. Presentation resembles foodborne disease, but onset is typically more gradual, and relapsing symptoms during treatment can occur from ongoing intraluminal toxin production.[2]
Risk Factors
- Home-canned, home-preserved, or fermented foods not processed to eliminate C. botulinum spores or prevent toxin formation — home-canned vegetables, cured meats and ham, and smoked or fermented fish are the most frequently implicated categories.[6][7]
- Traditionally prepared, fermented marine-mammal and fish products (seal, whale, walrus, fermented fish eggs) made without refrigeration — a well-documented, though substantially reduced, source of foodborne (largely toxin type E) botulism in northern and Indigenous communities in Canada; see Special Populations.[7][2]
- Injection drug use, particularly subcutaneous or intramuscular injection ("skin-popping") of black tar heroin — the dominant risk factor for wound botulism in North America.[2][8]
- Any traumatic or contaminated wound, including a compound fracture, even without drug use.[2]
- Infants younger than 12 months given honey in any form — the only food definitively linked to infant botulism, though it accounts for only a small proportion of cases.[9][2]
- Infants exposed to disturbed soil or household dust — a more common, though far less modifiable, source of the spores that cause infant botulism than honey.[2]
- Cosmetic or therapeutic botulinum toxin injection, especially with an unregulated, unlicensed, or counterfeit product, or at a dose or injection site outside approved use.[4][5]
- Immunocompromised status, recent antimicrobial therapy, inflammatory bowel disease, or prior gastrointestinal surgery altering gut flora or anatomy — risk factors specific to adult intestinal colonization botulism.[2]
Red Flags & Refer
Botulism is a medical emergency from the moment it is suspected — not once it is confirmed. Any of the following should trigger immediate emergency referral and, in parallel, immediate notification of local public health:
- New diplopia, ptosis, dysarthria, dysphonia, or dysphagia — especially if bilateral/symmetric, afebrile, and without sensory symptoms.[2][1]
- Any descending pattern of weakness, from cranial nerves toward the limbs and trunk.[1]
- Any shortness of breath, weak cough, or difficulty handling secretions in a patient with the above findings — treat as impending respiratory failure until proven otherwise.[1]
- An infant younger than 12 months with new constipation plus poor feeding, a weak or altered cry, loss of head control, or floppiness — do not wait for a clear honey or soil-exposure history before escalating.[2]
- A known or suspected shared food exposure with another person now showing compatible symptoms — treat every case of foodborne botulism as a potential public health emergency, since others may share the same unrecognized exposure.[2]
- Recent cosmetic or therapeutic botulinum toxin injection with new generalized weakness, dysphagia, or respiratory symptoms, particularly from an unregulated source or an unusually large/off-label dose.[4][5]
The pharmacist's role here is recognition and immediate escalation — not outpatient assessment, symptomatic treatment, or a "wait and see" approach. Arrange emergency transport/transfer, and ensure the receiving team and local public health authority (Medical Health Officer) are both notified as soon as possible; botulism is a nationally reportable disease in Canada, and rapid notification is what sets antitoxin access in motion.[2][10]
Assessment & Diagnosis
Botulism is a clinical diagnosis — treatment must never wait for laboratory confirmation
Diagnosis rests on history and a thorough, serial neurologic examination. Confirmatory testing typically takes days to complete and can be falsely negative even in genuine disease, so the diagnostic and treatment decision has to be made on clinical grounds.[2][1][3] Current guidance specifically recommends considering botulism whenever myasthenia gravis or Guillain-Barré syndrome is being considered, and in any patient with unexplained, symmetric cranial nerve palsies with or without other muscle weakness.[1]
Differentiating botulism from its principal mimics
Botulism is frequently misdiagnosed, most often as Guillain-Barré syndrome (or its Miller Fisher variant), myasthenia gravis, or a primary CNS event such as stroke.[1] The pattern below is the most useful bedside discriminator.
| Feature | Botulism | Guillain-Barré syndrome | Myasthenia gravis |
|---|---|---|---|
| Pattern of weakness | Symmetric, descending — starts with cranial nerves | Classically ascending — starts distally in the legs | Fluctuating and fatigable; often ocular/bulbar early, but does not follow a true descending pattern |
| Sensory findings | None | Often present — paresthesias, sensory loss | None |
| Fever | Absent, unless a complicating infection is present | Usually absent | Absent |
| Pupils | Often dilated and sluggish, or fixed (autonomic involvement) | Normal | Normal |
| Mental status | Alert and oriented throughout | Alert and oriented throughout | Alert and oriented throughout |
| CSF protein | Normal | Often elevated (albuminocytologic dissociation) | Normal |
| Repetitive nerve stimulation | An increment in compound motor action potential amplitude at high-frequency stimulation (30-50 Hz) | Normal, or reduced amplitude without an increment | A decrement in amplitude at low-frequency stimulation |
Electrodiagnostic testing
Electromyography, repetitive nerve stimulation, and nerve conduction studies can support the diagnosis when the picture is unclear. Classical findings include an incremental response to repetitive nerve stimulation at 30-50 Hz, fibrillation, decreased recruitment of motor units, decreased motor unit potential duration, and decreased motor-evoked amplitude on nerve conduction studies with otherwise normal findings — though testing can be entirely normal early in the illness, and is not needed to justify starting antitoxin when the clinical picture is already convincing.[1]
Laboratory confirmation
Confirmation relies on detecting botulinum toxin (by mouse bioassay, the diagnostic gold standard, or by newer immunoassay/cell-based methods) in serum, stool, gastric aspirate, wound tissue, or suspect food, or on isolating C. botulinum itself from stool, gastric aspirate, or a wound. Whenever feasible, collect serum for toxin testing before antitoxin is given, since antitoxin will neutralize circulating toxin and can produce a false-negative result — but this should never delay treatment itself.[2][1]
| Subtype | Confirmed-case laboratory criteria (with compatible clinical illness) |
|---|---|
| Foodborne | Detection of botulinum toxin in serum, stool, gastric aspirate, or food, or isolation of C. botulinum from stool or gastric aspirate |
| Wound | Detection of toxin in serum or isolation of C. botulinum from a wound, with a freshly infected wound in the preceding 2 weeks and no compatible food exposure |
| Infant (younger than 1 year) | Detection of toxin in stool or serum, or isolation of C. botulinum from stool or at autopsy |
| Adult intestinal colonization (1 year or older) | Detection of toxin in stool or serum, or isolation of C. botulinum from stool or at autopsy, in a patient with severely disrupted gastrointestinal flora or anatomy |
Routine bloodwork (CBC) and, where a lumbar puncture is performed, CSF studies are typically normal in botulism — a genuinely useful negative finding, since an elevated CSF protein points toward Guillain-Barré syndrome instead.[1] Because manipulating botulinum toxin and viable C. botulinum carries its own laboratory biosafety requirements, testing is performed only at a designated public health reference laboratory — notify local public health immediately once botulism is suspected so that specimen collection and shipment, and the parallel process of arranging antitoxin, can proceed together rather than sequentially.[2]
Treatment Targets
- Halt further progression of paralysis with antitoxin as early as possible — antitoxin cannot reverse paralysis that has already occurred, so speed matters more than for almost any other therapy in this platform's library.
- Protect the airway and support ventilation proactively, before overt respiratory failure develops.
- Achieve source control for wound botulism through debridement and drainage.
- Prevent further toxin absorption or production where relevant (removing unabsorbed foodborne toxin from the gut, treating a local wound infection).
- Provide meticulous supportive and nutritional care through what can be a weeks-to-months recovery, since this — more than any single drug — is what has driven the case-fatality rate down over the past century.
- Notify public health immediately and support the outbreak investigation for foodborne cases, to identify and protect other people who may share the same exposure.
- Educate the patient, family, or caregiver on the specific prevention point relevant to their case — honey avoidance, safe home-canning practice, or harm-reduction guidance — to prevent a recurrence.
Choose Initial Treatment
Treat on clinical suspicion — do not wait
Initiate antitoxin as soon as botulism is clinically suspected, in parallel with — never after — public health notification and specimen collection. Antitoxin is most effective when given within 24 hours of symptom onset, and current guidance frames within 48 hours as the treatment window; it does not reverse existing paralysis, but it prevents further binding of circulating toxin and measurably reduces the length of mechanical ventilation, ICU stay, and hospitalization.[2][1] For a patient presenting later in the illness: if symptoms or signs (including paralysis) are still progressing, treat with antitoxin regardless of how much time has passed; if the patient is not progressing and has no remaining voluntary muscle function, benefit is less likely, especially beyond 7 days, since circulating toxin is infrequently detectable by that point.[1] Pregnancy is not a contraindication to antitoxin.[1]
Which antitoxin, and how to access it in Canada
Two distinct antitoxin products exist, and neither is stocked for routine use or approved for sale in Canada — both require an emergency application through Health Canada's Special Access Programme (SAP), coordinated through the local Medical Health Officer and the provincial public health laboratory/CDC.[2]
BAT vs. BabyBIG
BAT — Botulism Antitoxin Heptavalent (equine-derived)
Preferred, all ages for children and adults with symptomatic, non-infant botulism of any toxin type (A through G), and for infant botulism specifically not caused by type A or B. The treating physician (via the local Medical Health Officer) submits a Health Canada SAP Request Form A by fax, with a same-time follow-up phone call to the SAP office; provincial public health then authorizes release and shipment of the antitoxin held at the provincial pharmacy/CDC.[2] Because BAT is equine-derived, assess hypersensitivity risk to equine protein (a prior reaction, or repeated past antitoxin exposure) before administration, and consider skin testing plus having anaphylaxis treatment on hand for higher-risk patients — but an increased allergy risk is not itself a reason to withhold antitoxin.[2]
BabyBIG — Botulism Immune Globulin Intravenous, human-derived
Preferred for infants under 1 year, types A or B BabyBIG is human-plasma-derived, is not associated with the equine-hypersensitivity risk of BAT, and reduces the duration of hospitalization, mechanical ventilation, and tube feeding in confirmed infant botulism caused by type A or B.[2][11] It is supplied only through the California Department of Public Health's Infant Botulism Treatment and Prevention Program; the treating physician contacts the program's on-call physician directly (24/7) to review indications and arrange shipment, in parallel with a separate Health Canada SAP approval.[2] Dose: 1.0 mL/kg (50 mg/kg) as a single IV infusion.[2] Infant botulism due to a type other than A or B is treated with BAT instead.[2]
Wound botulism — antibiotics have a role here, but only for source control
Wound botulism in addition to antitoxin, debride the wound and establish drainage, and treat any secondary/local wound infection with an antibiotic — antibiotics do not neutralize circulating toxin, only the local bacterial infection.[2] Avoid aminoglycosides they independently potentiate neuromuscular blockade and can worsen the paralysis itself.[1][2] Use caution with clindamycin and penicillins current guidance flags both as carrying a theoretical risk in botulism and recommends weighing risks and benefits individually against any comorbid indication, rather than reaching for either by default.[1]
Do not use antibiotics to treat the toxin itself
Foodborne, infant, and adult intestinal colonization botulism antibiotics are not recommended for these forms specifically because there is no infected wound to treat — lysis of C. botulinum by an antibiotic could theoretically increase the amount of toxin released and available for absorption.[2]
No other proven pharmacotherapy
No other agent has been shown effective for botulism, including activated charcoal, polyethylene glycol, cholinergic agonists, or plasmapheresis; use magnesium, calcium, monoamine oxidase inhibitors, and neuromuscular blocking agents cautiously if at all, since each can plausibly worsen neuromuscular transmission in a patient already close to respiratory failure.[1] Antitoxin is not useful as postexposure prophylaxis for an asymptomatic person with a shared exposure — monitor closely instead, and treat promptly with antitoxin at the very first sign of illness.[2][1]
Non-Pharmacologic Treatment
- Hospitalize every suspected case, with ICU-level monitoring and serial vital capacity measurement — the goal is a low threshold for elective intubation and mechanical ventilation, arranged calmly and in advance, rather than emergency intubation after overt respiratory failure develops.[1]
- Wound botulism: debride the wound and establish drainage in addition to antitoxin and antibiotics — this is core therapy, not an adjunct.[2]
- Provide nutritional support (nasogastric or parenteral, as needed) proactively, given the prolonged dysphagia and ileus that can accompany the illness.
- For a patient with a confirmed or strongly suspected foodborne exposure, and within an appropriate window, unabsorbed toxin remaining in the gastrointestinal tract may be purged with cathartics, gastric lavage, or a high enema, under close medical supervision — these measures are not used in infant botulism.[2]
- Arrange physical, occupational, and respiratory therapy proactively — recovery is genuinely protracted, often weeks to months, as new nerve terminals sprout to bypass the blocked synapses, and rehabilitation needs should be anticipated rather than addressed only once weaning begins.[1]
- Standard precautions are sufficient — no isolation is required, and no case of person-to-person transmission of botulism has been documented, including in healthcare settings.[1]
- Infants (and adult intestinal colonization patients) can shed C. botulinum organism and toxin in the stool for weeks to months after the acute illness resolves — reinforce hand hygiene for caregivers and careful handling and disposal of diapers at discharge.[1]
- Meticulous supportive and nutritional care is, alongside antitoxin, the other half of why the case-fatality rate has fallen from roughly 70% in the early 1900s to about 5-10% today — it is not merely an adjunct to drug therapy.[1][2]
Special Populations
Infants younger than 12 months
Infant botulism is the most commonly reported form of botulism in North America, most often affecting infants between 6 weeks and 6 months of age.[2] The single most important, actionable prevention message do not give honey — raw, pasteurized, or cooked/baked into any food, or added to a soother — to an infant younger than 12 months. Honey is the only food definitively linked to infant botulism in Canada, though it accounts for only a minority of cases; there were 38 reported cases of infant botulism in Canada between 1979 and 2010.[9] Disturbed soil or household dust is a more common, though far less modifiable, source of the spores that cause infant botulism.[2] BabyBIG (see Choose Initial Treatment) is the preferred antitoxin for confirmed type A or B infant botulism; BAT is used for other or unconfirmed toxin types.[2]
People who inject drugs
Maintain a high index of suspicion for wound botulism in any person who injects drugs — particularly black tar heroin injected subcutaneously or intramuscularly ("skin-popping") — presenting with unexplained cranial nerve findings, even if the injection site looks unremarkable and even if the patient does not volunteer a substance-use history.[2][8] A 2017-2018 outbreak among people who used black tar heroin in San Diego County illustrates how these outbreaks cluster and how easily individual cases can be missed early.[8] This encounter is also a genuine opportunity for harm-reduction counseling and referral, alongside the emergency botulism workup itself.
Indigenous and northern communities
Traditionally prepared, fermented marine-mammal and fish products (seal, whale, walrus, fermented fish eggs) made without refrigeration remain a recognized source of foodborne botulism — predominantly toxin type E — in northern and Indigenous communities in Canada, though the share of national cases arising from Indigenous communities fell from 85% (1990-2005) to 46% (2006-2021) following targeted risk-communication and food-safety education, particularly around promptly chilling butchered meat below 4°C.[7] The right response to this risk is honest, collaborative risk-reduction messaging about preparation and storage — not discouraging traditional food practices; in British Columbia, the First Nations Health Authority is specifically invited to participate in case management whenever a suspected case is Indigenous.[2]
Cosmetic and therapeutic botulinum toxin recipients
Iatrogenic botulism is rare but genuinely under-recognized, and has been reported even at doses used for routine cosmetic indications through unintended systemic spread of the toxin.[5] Recent outbreaks — including a cluster linked to unregulated botulinum toxin used for obesity treatment in Türkiye in 2023 — underscore that unlicensed product and off-label, excessive dosing are the dominant drivers.[4] Counsel patients considering cosmetic botulinum toxin injection to use only a licensed practitioner and an approved product (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, or letibotulinumtoxinA — see Drug Tables); if iatrogenic botulism is suspected, confirm exactly which product, dose, and injection site the patient received as part of the emergency workup.
Pregnancy
Pregnancy is not a contraindication to botulinum antitoxin — treat as aggressively and as promptly as in a non-pregnant patient, given the maternal respiratory risk of untreated disease, and involve obstetrics or maternal-fetal medicine early.[1]
Immunocompromised adults and altered gastrointestinal anatomy or flora
These patients are the population at risk for adult intestinal colonization botulism. Relapsing or fluctuating symptoms during otherwise adequate antitoxin treatment can occur because of ongoing intraluminal toxin production, and should prompt reconsideration of repeat antitoxin dosing and gastroenterology involvement for the underlying gastrointestinal abnormality, rather than being assumed to reflect treatment failure.[2]
Renal and hepatic impairment
No antitoxin dose adjustment is required for renal or hepatic impairment. Adjust supportive-care medications used during the ICU stay (sedation, analgesia, and any antibiotic given for wound botulism source control) according to their own usual organ-impairment principles.
Monitoring & Follow-Up
Monitor respiratory status closely and continuously through the acute illness — serial vital capacity measurement, with a proactive, low threshold for intubation and mechanical ventilation, is the standard rather than waiting for a dramatic clinical deterioration.[1]
- Anticipate a genuinely protracted recovery — paralysis can persist for weeks to months as new nerve terminals regenerate and reinnervate the neuromuscular junction — and arrange physical, occupational, and speech-language therapy (for dysphagia) proactively rather than only once ventilator weaning begins.[1][2]
- Infants and adult intestinal colonization patients can continue to shed C. botulinum organism and toxin in the stool for weeks to months after the acute illness resolves; reinforce caregiver hand hygiene and careful diaper handling/disposal at discharge, even though no person-to-person transmission has ever been documented.[1]
- Complete the required Health Canada SAP follow-up reporting (Form C) after any BabyBIG use, and ensure the case is formally reported to public health within the applicable provincial timeline if this was not already completed at presentation.[2]
- For foodborne cases, expect ongoing public health follow-up of household members and other people who may have shared the same food exposure, and continued food-source investigation — support this rather than treating it as complete once the index patient is stabilized.[2]
- At outpatient follow-up after discharge, reassess for residual weakness or fatigue, and screen for the psychological impact of a prolonged ICU stay and mechanical ventilation, which is easy to overlook once the acute paralysis has resolved.
Common Errors to Avoid
- Waiting for mouse bioassay or other laboratory confirmation — which can take days and can still be falsely negative — before starting antitoxin or escalating to emergency care.[2][1]
- Missing wound botulism in a person who injects drugs because the injection site looks unremarkable, or because the patient does not volunteer a substance-use history.[2][8]
- Giving any honey-containing food or product to an infant younger than 12 months.[9]
- Using an aminoglycoside for the wound infection in wound botulism — it independently potentiates neuromuscular blockade and can worsen the paralysis itself.[1]
- Reaching for antibiotics to try to treat foodborne, infant, or adult intestinal colonization botulism itself, rather than reserving them strictly for a documented secondary/local infection in wound botulism.[2]
- Treating the presence of fever or true sensory symptoms as consistent with botulism — either finding should prompt reconsidering the diagnosis rather than being explained away.[2][1]
- Delaying public health notification until the diagnosis feels fully confirmed, rather than notifying in parallel with treatment from the moment botulism is clinically suspected.[2]
- Treating a single case of foodborne botulism as an isolated event rather than a potential outbreak requiring prompt investigation of anyone who may share the same food exposure.[2]
- Assuming pregnancy is a contraindication to antitoxin — it is not.[1]
- Assuming BabyBIG is appropriate for every infant botulism case — it is specific to toxin types A and B; other or unconfirmed types need BAT instead.[2]
- Assuming a normal early electrodiagnostic study excludes botulism — testing can be entirely normal early in the illness.[1]
Clinical Decision Algorithm
Drug Tables
How to use this table: antitoxin doses require patient-specific confirmation through the access pathway described in Choose Initial Treatment; antibiotic doses require confirmation against local protocol, wound severity, and culture results. Select any drug name to open its complete Pharmasist Drug Database page.
Botulism Antitoxins
Neither product is stocked for routine use or approved for sale in Canada — both require an emergency Health Canada Special Access Programme application, coordinated through the local Medical Health Officer. See Choose Initial Treatment for the full access process.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| BAT — Botulism Antitoxin Heptavalent (equine-derived) | All eligible patients: Single slow IV infusion after 1:10 dilution in normal saline; age-banded dosing (under 1 year, 1-16 years, 17 years and older) per the product monograph | Hypersensitivity/anaphylaxis to equine protein, serum sickness | None specific; assess for prior antitoxin exposure, which increases hypersensitivity risk | For all ages beyond infancy, and for infants with a non-A/B or undetermined toxin type. Halts further paralysis but does not reverse existing weakness. |
| BabyBIG (Botulism Immune Globulin Intravenous, human-derived) | Infants, type A or B: 1.0 mL/kg (50 mg/kg) IV as a single infusion | Generally well tolerated; transient mild infusion reactions | None specific | Preferred for infants under 1 year with confirmed or strongly suspected toxin type A or B. Reduces duration of hospitalization, mechanical ventilation, and tube feeding. |
Wound Botulism — Antibiotics for the Local/Secondary Infection Only
These treat the wound infection itself, not the circulating toxin — debridement and drainage remain equally essential alongside antitoxin. Select and dose according to wound severity, culture results, and local protocol.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Metronidazole | Adults: 500 mg IV or PO every 8 hours, per local protocol | GI upset, metallic taste, peripheral neuropathy with prolonged use | Disulfiram-like reaction with alcohol | A reasonable choice for anaerobic wound coverage — it does not carry the neuromuscular-blocking pharmacology of aminoglycosides or clindamycin. |
| Penicillin G | Adults: Per infectious diseases consultation and local protocol | Hypersensitivity reactions | None significant at standard doses | Current CDC guidance flags a theoretical risk with penicillins in botulism specifically — weigh risk/benefit individually, ideally with infectious diseases input, rather than defaulting to it. |
Antibiotics to Avoid or Use With Caution in Any Form of Botulism
Listed because they are commonly reached for empirically in a patient with a wound or a presumed infection — in botulism specifically, each carries an added risk beyond its usual adverse-effect profile.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Gentamicin | Avoid: Not recommended in confirmed or suspected botulism | Nephrotoxicity, ototoxicity, PLUS independently potentiates neuromuscular blockade | Additive nephro/ototoxicity with vancomycin or other nephrotoxins | Avoid for wound botulism source control regardless of culture susceptibility — can worsen the paralysis itself. |
| Tobramycin | Avoid: Not recommended in confirmed or suspected botulism | Nephrotoxicity, ototoxicity, PLUS independently potentiates neuromuscular blockade | Additive nephro/ototoxicity with other nephrotoxins | Same aminoglycoside-class concern as gentamicin — avoid. |
| Clindamycin | Use with caution: Only per individualized risk/benefit assessment | Clostridioides difficile-associated diarrhea, GI upset | None significant at standard doses | Current CDC guidance flags a theoretical neuromuscular risk in botulism specifically — use only if no reasonable alternative exists, weighing risk/benefit individually. |
Cosmetic/Therapeutic Botulinum Toxin Products — Relevant to Iatrogenic Botulism, Not a Treatment for It
Included so the pharmacist can confirm exactly which product, dose, and injection site a patient received when iatrogenic botulism is suspected — none of these treats botulism itself.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| OnabotulinumtoxinA | Approved use: Per the product's own Drug Database monograph | Generalized weakness, dysphagia, or respiratory compromise if toxin spreads systemically (rare at approved doses) | Additive effect with aminoglycosides or other neuromuscular-blocking drugs | See the linked Drug Database entry for the approved dose and indication; iatrogenic botulism reflects a dose, technique, or product outside that approved use. |
| AbobotulinumtoxinA | Approved use: Per the product's own Drug Database monograph | Same class-wide systemic-spread risk as above | Additive effect with aminoglycosides or other neuromuscular-blocking drugs | Unit dosing is not interchangeable between botulinum toxin products — confirm exactly which product a patient received. |
| IncobotulinumtoxinA | Approved use: Per the product's own Drug Database monograph | Same class-wide systemic-spread risk as above | Additive effect with aminoglycosides or other neuromuscular-blocking drugs | Confirm the product source is a licensed supply — unregulated/counterfeit product is a recurring theme in reported iatrogenic outbreaks. |
| PrabotulinumtoxinA | Approved use: Per the product's own Drug Database monograph | Same class-wide systemic-spread risk as above | Additive effect with aminoglycosides or other neuromuscular-blocking drugs | Confirm the specific product, dose, and injection site whenever iatrogenic botulism is suspected. |
| LetibotulinumtoxinA | Approved use: Per the product's own Drug Database monograph | Same class-wide systemic-spread risk as above | Additive effect with aminoglycosides or other neuromuscular-blocking drugs | Confirm the specific product, dose, and injection site whenever iatrogenic botulism is suspected. |
References
- Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 — MMWR Recommendations and Reports, Centers for Disease Control and Prevention (Rao AK, Sobel J, Chatham-Stephens K, Luquez C). MMWR Recomm Rep 2021;70(No. RR-2):1-30
- Communicable Disease Control Manual, Chapter 1 – Management of Specific Diseases: Botulism — BC Centre for Disease Control. BCCDC Communicable Disease Control Manual, May 2023
- Botulism — CMAJ (Fraser B, Halani S, Sharma M). CMAJ 2025;197(1):E13
- Cases of iatrogenic botulism in individuals who underwent treatment for obesity in Türkiye — World Health Organization Regional Office for Europe. WHO/Europe News, March 24, 2023
- Iatrogenic Botulism Following Cosmetic Botulinum Toxin Injection Presenting With Respiratory Distress: A Case Report — Cureus (Zahur H, Malik J, Arshad L). Cureus 2025
- Botulism: Guide for Healthcare Professionals — Public Health Agency of Canada / Health Canada. Government of Canada Guidance Document, 2012 (updated 2016)
- Foodborne Botulism, Canada, 2006–2021 — Emerging Infectious Diseases (Harris RA, Tchao C, Prystajecky N, Weedmark K, Tcholakov Y, Lefebvre M, Austin JW). Emerg Infect Dis 2023;29(9):1730-1737
- Wound Botulism Outbreak Among Persons Who Use Black Tar Heroin — San Diego County, California, 2017–2018 — MMWR Morbidity and Mortality Weekly Report (Peak CM, Rosen H, Kamali A, et al.). MMWR Morb Mortal Wkly Rep 2019;67(51-52):1415-1418
- Preventing botulism in infants — Health Canada. Health Canada News Release, March 28, 2011
- National case definition: Botulism — Public Health Agency of Canada. Government of Canada, Case Definitions for Communicable Diseases
- Infant Botulism Treatment and Prevention Program — California Department of Public Health. CDPH Infant Botulism Treatment and Prevention Program
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.